These novel insights strongly suggest that inhibition of MEK–ERK or PI3K/AKT/mTOR signaling could enhance steroid sensitivity in T-ALL and potentially improve patient treatment outcome, a notion that warrants further investigation in future prospective clinical trials. Here, MTOR is linked to acute lymphoblastic leukemia.